Aimed S.A.S.
- Address
- lock Available on a paid plan
Physical Phenomena and Aesthetic Medicine
The clinical research at Aimed S.A.S. in Lyon focuses on physical phenomena and appearance-related care, with studies centered on improving visible facial concerns in adults. The trials are designed to assess the safety and effectiveness of new approaches for reducing the appearance of moderate to severe upper facial lines.
- Research on upper facial lines, including glabellar and forehead-related wrinkles
- Evaluation of treatments aimed at improving facial appearance and patient-reported satisfaction
- Testing the safety and tolerability of new aesthetic therapies versus placebo
This work helps advance treatment options for people seeking non-surgical solutions for visible facial aging and supports better understanding of how these therapies perform in real-world use.
Facial Muscle-Related Prominence and Cosmetic Treatment Research
Another key area of study at this French research site involves moderate to severe platysma prominence, a condition linked to visible neck muscle bands and contour changes. The trials are evaluating whether investigational treatments can safely improve appearance compared with placebo.
- Studies in platysma prominence and related aesthetic concerns of the neck
- Assessment of treatment benefit in improving visible lines and muscle-related prominence
- Safety and efficacy research for adults with moderate to severe cosmetic concerns
These studies contribute to the broader field of aesthetic medicine by exploring ways to refine treatment effectiveness and offer better options for adults looking to address facial and neck appearance concerns.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Ipsen Innovation1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aimed S.A.S.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Safety and Efficacy of IPN10200 in Adults with Moderate to Severe Upper Facial Lines: A Randomized, Double-Blind, Placebo-Controlled Study | Ipsen Innovation | Phase I/II | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Botulinum Toxin Type A - Haemagglutinin Complex | 1 | Unknown | 2024-03-20 | 2024-03-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.